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Abstract The bronchodilating properties of formoterol from a novel multi-dose inhaler, Airmaxs 6 mg and from a
single-dose drypowderinhaler ForadilsAerolisers12 mgwere investigatedin 31adult asthmaticswith FEV1X60%pre-
dicted and a reversibilityX12%.Patients received on a single day fourdoses of formoterol: cumulative dose 6,12, 24 and
48 mg fromAirmax, or12, 24,48 and 96 mg fromAerolisers.Themean FEV1 (SD) frombaselineto1h after the final cumu-
lative dose increased by 0.81l from 2.62 (0.58) to 3.43 l (0.70) with Airmaxs and by 0.85 l from 2.65 (0.60) to 3.5 l (0.68)
with Aerolisers. All 90% CIs for all fourdose comparisonswerewithin the equivalence range70.1l.Therewas a higher
incidence of hypokalaemia and hyperglycaemia at highest doses during treatment with the Aerolisers than with Air-
maxs. In conclusion, formoterol delivered from Airmaxs provides a dose-dependent bronchodilating effect which is
similar to thatobtained by Aerolisers atdouble the dose.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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cumulative doses.INTRODUCTION
Long-acting b2-agonists are used in asthma as an adjunct
to anti-in£ammatory therapy, increasing long-term con-
trol of symptoms, reducing frequency of exacerbations
and improving quality of life (1^3). Formoterol is a long-
acting b2-agonist with a fast onset of action comparable
to thatof salbutamol and a duration of action of up to12h
(4,5). It has been developed for delivery by inhalation,
both by pMDI and by dry powder inhaler (DPI). Air-
maxs is a novel inhaler (Fig.1) which utilises proprietary
technologyknown as theX-ACTtsystem (active-meter-
ing, cyclone-separator technology) designed to provide
accurate and consistent dosing largely independent of in-
spiratory £ow-rate (6).The inhaler has a dose reservoir
containing 60 doses of formoterol at two strengths 6 and
12mg, is resistant to humidity and is equippedwith a dose
counter. In vitro gravimetric and multistage liquid impin-
ger assessments with formoterol Airmaxs have
shown high dose consistency (relative standard devia-
tions between 2.5 and 3.5%), and emitted doses close toReceived 20 December 2001, accepted in revised form17 May 2002
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dose or the respirable dose (o5.8mm) delivered from
Airmaxs formoterol 6mg strength is 2.5mg (7). This is
similar to that from the single-dose inhaler Aerolisers
(i.e. 2.1mg) atdouble the dose, i.e.12mgper actuation (8).
The aim of this study was to assess and compare the
bronchodilating e¡ects of formoterol from the multi-
dose inhaler Airmaxs with formoterol from the single-
dose inhaler Foradils Aerolisers at a1:2 dose ratio.
METHODS
Patients
Eligible study participants, selected from the outpatient
department of a hospital and from a GP practice in the
Netherlands, were adults (aged 18^45 years) with a
documented clinical history of asthma of at least 6
months, a FEV1 ofX60% of the predicted normal value
for age, height and gender (21) and FEV1 reversibility of
X12% after administration of salbutamol (400mg) from
a pMDI via a spacer device (Volumatics, GlaxoSmith
Kline). Patients were excluded if they had received
oral corticosteroids or any other investigational
medication within the previous 3 months, or had re-
ceived emergency treatment or been hospitalised
FIG. 1. Diagramof Airmaxswith stage1 (activemetering) and stage 2 (cyclone separator).
72 RESPIRATORYMEDICINEfor asthma within this period. On each treatment day,
patients were not to have used bronchodilators in the
previous12h.
Study design
The study was conducted according to an open, rando-
mised, two period crossover design in accordance with
the Declaration of Helsinki (South Africa, October
1996) and was approved by the local independent ethics
committee. Eligible patients, having given written in-
formed consent, were randomised to their ¢rst treat-
ment at the ¢rst visit, receiving the alternate treatment
at the following visit 2^14 days later. Seven to 14 days
thereafter, a follow-up visit post-study took place. On
each treatment day patients received four cumulative
doses of formoterol at the following time points: 0(baseline), 70, 140 and 210min. Doses given from the
Aeroliserswere12,12, 24 and 48mg, representing cumu-
lative doses of12, 24, 48 and 96mg, whilst doses from the
Airmaxs were half of the above, i.e. 6, 6, 12 and 24mg
representing cumulative doses of 6, 12, 24 and 48mg.
FEV1 was measured 1h post each dose and 10min be-
fore ¢rst dose and at 15min post ¢rst dose. In order to
exclude non-responders on a particular study day, the
study visit of patients failing to demonstrate and increase
of FEV1ofX12% 15min after the ¢rst dosewas deferred
for up to 7 days.
Safety assessments
Vital signs and a 12-lead electrocardiogram were re-
corded at each clinic visit, both before and after dosing
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FIG. 2. Percentage increase in FEV1 (7SD) from baseline fol-
lowing cumulative doses of 6,12, 24,48 mg formoterol from Air-
maxsor12, 24,48,96 mg fermoterol fromForadilsAcrolisersin
30 asthma patients.
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matological parameterswere also assessed on each study
day. A complete physical examination was carried out at
screening and at the post-study visit. Adverse events
were reported at each of the post-screening visits.
Statistical analyses
The analysis was performed on the per protocol popula-
tion consistingof all patientswho compliedwith the pro-
tocol without any major deviations. Four pairwise
comparisons were conducted by analysis of variance
(ANOVA), one for each cumulative dose level.The depen-
dent variable was the absolute change (or percentage
change ) in FEV1 1h after each dose, with patient, visit
and treatment as ¢xed factors.Conventional 90% con¢-
dence intervals for equivalence were computed around
the di¡erences in response at each dose level. Power cal-
culations required a minimum of 27 patients to be in-
cluded into the analysis in order to achieve a power of
80% to show equivalence on all four dose comparisons
assuming a standard deviation of 3% in FEV1.
RESULTS
Frommedical records 31patients were invited to partici-
pate, all of whom were randomised to treatment, and
comprised the safety population.One patient was lost to
follow-up after the ¢rst treatment day (with Airmaxs)
andhence theper protocol e⁄cacypopulation comprised
the 30 patients. Patient demographic data and main con-
comitant asthmamedications are shown inTable1.
Themean FEV1 (SD) from baseline to1h after the ¢nal
cumulative dose increased by 0.81l from 2.62 (0.58) to
3.43 l (0.70) with Airmaxs and by 0.85 l from 2.65 (0.60)
to 3.5 l (0.68) with Aerolisers (Fig. 2).This corresponds
to a mean maximum percentage increase of 32.4 and
34.0% after Airmaxs and Aerolisers, respectively. On-
set of action was rapid and 15min after the ¢rst dose
mean FEV1 had increased by 19.2% with Airmax
s 6mgTABLE 1. Patientdemographics
N All
31
Mean age (7SD) years 30.4 (8.0)
Range 18^43
Males:females (N) 15:16
Caucasian: Asian (N) 30:1
Meanweight (7SD) kg 74.6 (14.2)
Range (kg) 51^105
Meanheight (7SD) cm 173.2 (7.4)
Range (cm) 160^189and by 20.8% with Aerolisers 12mg.The 90% CIs for all
four dose comparisons were within the equivalence
range 70.1l and within 75% (Table 2). Fifteen adverse
events (10 mild, ¢vemoderate), all considered to be unli-
kely to relate to study treatment, were reported by 10
patients. Post-dosing serum potassium levels and blood
glucose were below normal in ¢ve patients and above
normal in eight patients, respectively on Airmaxs. On
Aerolisers10 patients had a drop in serumpotassium le-
vels and 16 patients had a rise in blood glucose. In only
two patients (both on Aerolisers) the serum potassium
levelswerebelow 3.2mmol/l andconsideredclinically re-
levant.Therewere no clinically relevant changes in blood
pressure or heart rate.Therewere no clinical abnormal-
ities in the ECG except for biphasicT-top due to low po-
tassium in the two patients.
DISCUSSION
In this study formoteroldeliveredby themulti-dose inhaler
Airmaxs provided a rapid anddose-relatedbronchodilata-
tion in adult asthmatic patients. The results suggest that
formoterol givenvia Airmaxs is approximately equipotent
to formoterol givenvia Aerolisers atdouble the dose.This
is in line with in vitro pharmaceutical data showing a respir-
able (or ¢ne particle) dose of formoterol approximately
twice as highwith Airmaxs thanwith Aerolisers.
The dose^response e¡ect of formoterol on the de-
gree of bronchodilatation was sustained and consistent
with observations from previous studies (9,10) being
comparable between the two devices at all time points.
The results were supported by an analysis of percentage
changes in FEV1which showed that when based on per-
TABLE 2. Absolute change andpercentage change in FEV1for Airmax
s vs.Aerolisers in 31asthmatic patients (ANOVA)
Treatments Meandi¡erencewith 90% con¢dence limits (l and %)
Airmaxs (mg) Aerolisers (mg) Lower Di¡erence Upper
6 12 0.08 (3.6%) 0.02 (0.6%) 0.05 (2.5%)
12 24 0.10 (4.7%) 0.04 (1.6%) 0.03 (1.4%)
24 48 0.09 (4.1%) 0.03 (1.1%) 0.04 (2.0%)
48 96 0.10 (4.6%) 0.04 (1.6%) 0.03 (1.5%)
74 RESPIRATORYMEDICINEcentage changes the di¡erence at each dose level lay en-
tirely within the range [5%, +5%]. The cumulative
dose^response design has been widely employed in the
assessment of bronchodilator drugs since its ¢rst intro-
duction in 1973 (11). After single doses of a short-acting
inhaled b2-agonist a plateau is reached after approxi-
mately 30min (12), in contrast to the e¡ect of cumulative
doses in which a continuous increase in elicited e¡ect is
seen, even at doses higher than the normal clinical doses
(13) an e¡ect which may be related to increased periph-
eral lung deposition resulting from the bronchodilation
produced by the initial dose.
In the present study formoterol 6mg from Airmaxs
and 12mg from Aerolisers displayed a very similar and
rapid onset of action and15min post ¢rstdose increased
FEV1by an average of 20%.Other studies (14,15) have ob-
served that whilst peak FEV1 values were not di¡erent
between varying doses of formoterol, onset of action is
faster and duration of action is longer when comparing
6mg with 12 and 24mg. Therefore, in order to con¢rm
the 1:2 dose relation between Airmaxs and Aerolisers
further studies comparing duration of action at di¡erent
doses are still required.
The systemic e¡ects observedwith inhaled formoter-
olwere dose-related.Therewere twice asmanypatients
withhypokalaemia andhyperglycaemia in theAerolisers
group compared to the Airmaxs group after the maxi-
mumdose of formoterolwas administered.The adminis-
tration of formoterol at half the dose from Airmaxs
could therefore o¡er some safety advantages over Fora-
dil Aerolisers but this should be con¢rmed in long-term
studies.
In conclusion, formoterol 6^48mg delivered from the
multi-dose inhaler Airmaxs provides a dose-dependent
clinically signi¢cant bronchodilating e¡ect which is simi-
lar to that obtained by the single-dose inhaler Aeroli-
sers at double the dose.
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